STM JOURNALS

Research & Reviews: A Journal of
Immunology

ISSN: 2277-6206 (Online)
ISSN: 2349-1280 (Print)
Volume 13, Issue 2, 2023
DOI (Journal): 10.37591/RRJoI

http://stmjournals.com/index.php?journal=RRJoI&page=index

Review RRJoI

Beyond Chemotherapy: The Promise of Immunotherapy in Cancer Care and Advancements in Cancer Therapy

Zaid Khan*

Abstract

Recent advances in cancer immunotherapy harness the immune system to precisely target cancer. These include the use of immunosuppressive agents, NK cell recovery, changes in tumor microenvironment metabolic, and aging to achieve a positive tumor response. The study explores the body development of the immune system in the late 19th century, highlighting milestones such as the discovery and FDA approval of IL2. Different categories of immunology are explored, from monoclonal antibodies to CAR-T cell therapies, with emphasis on potential and challenges. It emphasizes the role of the immune system in cancer prevention and includes drugs that block the immune system, such as PD-1/PD-L1 and CTLA-4 blockers, their approaches, clinical success, and combination therapies are discussed. The promising field of CAR-T cell therapy is broad, including technology, product development, challenges, future prospects and availability. In addition, oncolytic viruses such as T-VEC and HSV-1-based therapy show promise in cancer treatment. Ongoing research has been published on the treatment of oncolytic viruses for a variety of cancers, including triple negative breast cancer. Although challenges such as resistance to therapy remain, future developments include neoantigen vaccines, personalized medicine and nanomedicines to enhance drug delivery and reduce side effects. Immunotherapy dramatically extends patients' lives and improves their quality of life, offering hope for advanced cancer treatment.

Keywords: Immunotherapy, cancer care, quality of life, Natural Killer (NK) cells, cytokine-based therapies, tumor antigen escape

INTRODUCTION

Immunotherapy, a cancer treatment method, harnesses the body's immune system to fight against malignant cells. It has become an essential tool in cancer therapy due to its ability to specifically target cancerous cells while preserving the integrity of normal cells. Here are some noteworthy functions of immunotherapy in cancer treatment.

The Significance of Immunotherapy in Cancer Treatment

1. *PD-1/PD-L1 checkpoint inhibitors:* refer to medications that hinder the interaction between PD-1, a protein present on immune cells, and PD-L1, a protein found on cancer cells. This interaction has the potential to impede the immune system's ability to detect and eliminate cancer cells. By obstructing this interaction, PD-1/PD-L1 inhibitors assist the immune system in recognizing and fighting against cancer cells [1].
2. *Natural killer (NK) cells:* a specific type of immune cells, play a crucial role in identifying and eliminating cancer cells. However, the effectiveness of NK cells can be hindered by exosomes released by cancer cells. Fortunately, immunotherapy offers a promising solution to rejuvenate NK cell functionality and enhance their ability to eradicate cancer cells [2].

***Author for Correspondence**
Zaid Khan
E-mail: zaidkhan9515@gmail.com

Research Scholer, Department of Pharmacy Practice, Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore, Karnataka, India

Received Date: October 16, 2023
Accepted Date: October 18, 2023
Published Date: November 06, 2023

Citation: Zaid Khan. Beyond Chemotherapy: The Promise of Immunotherapy in Cancer Care and Advancements in Cancer Therapy. Research & Reviews: A Journal of Immunology. 2023; 13(2): 22–37p.

3. *Metabolic reprogramming of tumor microenvironment:* The metabolic landscape surrounding tumors undergoes re-configuration, enabling tumor cells to manipulate their immediate environment for enhanced growth and survival. Immunotherapy intervenes in these alterations by modifying the metabolic characteristics of the tumor microenvironment, making it less supportive of cancer cell sustenance while promoting immune cell function [3].
4. *Senescence induction:* The induction of senescence, a phenomenon where cells stop dividing and enter a growth cessation phase, has been studied in experimental models of ovarian cancer. It has shown to play a role in influencing both the susceptibility and resistance to chemotherapy and immune checkpoint inhibition. Leveraging the senescence mechanism could potentially enhance ovarian tumor responsiveness to immune checkpoint blockade therapy [4].

Immunotherapy has shown tremendous promise in the treatment of various types of cancer, emerging as a vital tool in the battle against this disease (Table 1).

The Historical Context of Cancer Treatment and How Immunotherapy Has Evolved

Immunotherapy, a remarkable breakthrough in cancer treatment, focuses on enhancing the body's natural defenses to eradicate malignant cells. This groundbreaking approach has revolutionized the field of oncology and offers immense hope for patients fighting against this formidable disease [5]. The concept of using immunotherapy in cancer treatment dates back to the late 19th century. It was William Coley, known as the father of immunotherapy, who first explored leveraging the immune system to combat cancer. He made this groundbreaking attempt after observing that a combination of live and inactivated *Streptococcus pyogenes* and *Serratia marcescens* could trigger spontaneous remission in certain cancer patients [6]. During the mid-1980s, an exciting breakthrough occurred as researchers discovered that the use of interleukin-2 (IL2), a cytokine, showed promising results in reducing or even eliminating tumors in certain cancer patients. This groundbreaking finding sparked the development of various other cytokine-based therapies [7].

Large doses of IL-2 were found effective in patients with advanced cancers by boosting T-cell production. Eventually, IL-2 gained FDA approval as an immunotherapeutic agent for metastatic kidney cancer in 1991 and metastatic melanoma in 1998 [8].

The environment of cancer treatment has been transformed by immunotherapy, offering effective new therapy options for various solid tumors and blood cancers [9]. Significant progress has been made in recent years through both basic and clinical investigations in the field of immunotherapy for cancer treatment. Various categories of immunotherapy have been developed and successfully implemented (Table 2) [2].

Table 1. Types of immunotherapies in cancer treatment.

Type of immunotherapy	Function/description
PD-1/PD-L1 Checkpoint Inhibitors	Block the interaction between PD-1 and PD-L1, aiding the immune system in recognizing and fighting cancer cells: Notable example is Pembrolizumab, Nivolumab
Natural Killer (NK) Cells	Enhance NK cell functionality and their ability to eliminate cancer cells by targeting exosomes released by cancer cells
Metabolic Reprogramming of Tumor Microenvironment	Modify the metabolic characteristics of the tumor microenvironment to make it less supportive of cancer cells and promote immune cell function
Senescence Induction	Influence the susceptibility and resistance of cancer cells to chemotherapy and immune checkpoint inhibition by inducing cellular senescence

Table 2 Historical development of immunotherapy in cancer treatment.

Milestone/Event	Description
Late 19th Century: William Coley	Father of immunotherapy, first explored using the immune system to combat cancer
Mid-1980s: Interleukin-2 (IL2) discovery	Showed promising results in reducing or eliminating tumors in certain cancer patients
1991 and 1998: FDA approval of IL-2	Approved as an immunotherapeutic agent for metastatic kidney cancer and metastatic melanoma
Recent years: progress in cancer immunotherapy	Development and successful implementation of various immunotherapy categories

These Include

1. *Monoclonal antibodies:* offer a promising solution. By targeting specific chemical components of cancer cells, scientists can produce these antibodies in large quantities. This treatment has proven effective in prolonging the lives of certain men with prostate cancer, although it should be noted that it does not provide a cure for the disease [10].
2. *Cytokine based therapies:* have been developed to enhance T-cell production and potentially reduce or eliminate tumors in certain patients. It is fascinating how these treatments aim to target specific.
3. *Cell based therapies:* involve isolating T cells from a patient's tumor, which are crucial infection fighting cells in the body. These T cells are then cultivated in the laboratory using cytokines before being reintroduced into the patient's system for treatment.
4. *Chimeric antigen receptor (CAR) T-cell therapy:* T cells isolated from a patient's blood are modified to express a CAR that will ideally enable the cell to recognize and destroy cancer cells by breaking it into shorter sentences while maintaining clarity [7].

OVERVIEW OF CANCER IMMUNOTHERAPY

Cancer immunotherapy is a treatment that utilizes the body's own immune system to fight against cancer [11]. This can be achieved through active immunotherapy, which directly activates immune responses using components of the immune system, or passive immunotherapy [12], which involves using cell based products and monoclonal antibodies to indirectly induce an immune response [13]. A combination of immunotherapies with other treatments like antiangiogenic agents may be a viable approach in treating cancer [14]. There are different types of immunotherapies available, including immune checkpoint inhibitors, adoptive cell transfer, and cancer vaccines [15]. Immunotherapy has become a crucial component in managing triple negative breast cancer successfully [16]. However, its effectiveness in treating pancreatic ductal adenocarcinoma is limited at present [17]. The m6A modification holds promise as a potential target for cancer immunotherapy, alongside immune checkpoint inhibitor therapies and chimeric antigen receptor T-cell therapy [18].

The Fundamental Principles of Cancer Immunotherapy

Cancer immunotherapy is a treatment approach that utilizes the immune system to combat cancer cells. The core principles underlying this therapy are:

1. *Immune recognition of cancer cells:* Cancer cells can be identified as foreign and potentially harmful by the immune system. This recognition is facilitated by immune cells, like T cells, that are capable of recognizing specific molecules on the surface of cancer cells known as antigens.
2. *Immune activation:* When our immune system detects cancer cells, it can be triggered to launch an attack and eliminate them. This process can happen in different ways, such as activating T cells or producing antibodies [19].
3. *Immune memory:* The immune system has the ability to remember cancer cells, enabling it to better recognize and respond to them in future encounters [20].
4. *Overcoming immune suppression:* One way that cancer cells can avoid detection and destruction by the immune system is by suppressing immune responses. In order to combat this, cancer immunotherapy seeks to counteract the suppression and strengthen the immune response against cancer cells.

There are several types of cancer immunotherapy, including immune checkpoint inhibitors, CAR T-cell therapy, cancer vaccines, and oncolytic viruses. These therapies work by different mechanisms but share the common goal of enhancing the immune system's ability to recognize and destroy cancer cells (Table 3) [21].

The Distinction Between Traditional Cancer Treatments and Immunotherapy

There are two types of cancer treatments: traditional cancer treatments, and immunotherapy. These conventional methods of treating cancer include surgery, chemotherapy and radiotherapy [22]. These include therapies that aim at eliminating cancer cells in the body. In surgery, cancerous tissues are extracted from a person's body while chemotherapy and radiation involve using medication and radiation to kill cancer cells. Alternatively, immunotherapy is a modern method of fighting cancer by utilizing the patient's immune system. The immunotherapy drugs function to aid the immune system in identifying and combating cancer cells. For instance, one type of immunotherapy drug is pembrolizumab (Keytruda), an approved US FDA humanized monoclonal anti-PD antibody for the treatment of advanced melanoma and NSCLC [23]. While conventional cancer treatments are still widely used, immunotherapy is turning into a more and more essential a part of most cancers' care. In reality, the difference between healing-cause and palliative-reason treatments has end up blurred, as increasingly, patients live with most cancers as a continual condition, transferring among remedy modalities as required. Additionally, immunotherapy has shown promising effects in treating cancers which can be resistant to standard remedies (Table 4) [24].

Table 3. Overview of cancer immunotherapy.

Type of immunotherapy	Description
Active immunotherapy	Directly activates immune responses using components of the immune system
Passive immunotherapy	Uses cell-based products and monoclonal antibodies to indirectly induce an immune response
Combination therapies	Combining immunotherapies with other treatments like antiangiogenic agents
Types of immunotherapies	Immune checkpoint inhibitors, adoptive cell transfer, cancer vaccines, and more
Application in cancer types	Effective in managing triple-negative breast cancer, limited effectiveness in treating pancreatic ductal adenocarcinoma
Potential targets for Immunotherapy	m6A modification, immune checkpoint inhibitors, chimeric antigen receptor T-cell therapy

Table 4. Comparison between traditional cancer treatments and immunotherapy.

Aspect	Traditional cancer treatments	Immunotherapy
Treatment methods	Surgery, chemotherapy, radiation therapy	Utilizes the patient's immune system to identify and combat cancer cells
Drug example	Chemotherapy drugs	Pembrolizumab (Keytruda)
Use in cancer care	Still widely used	Increasing importance in cancer care, showing promise in treatment-resistant cancers
Healing vs. palliative care	Distinction between healing and palliative care blurred, patients transition between modalities	Immunotherapy offers new hope in treating resistant cancers

The Importance of the Immune System in Cancer Control

The immune system plays a crucial role in cancer control. Here are some reasons why:

- The immune system can understand and assault cancer cells. Cancer cells frequently have bizarre proteins on their surface that can be identified with the aid of the immune machine as overseas.

Immune cells which include T cells and herbal killer cells can then target and spoil those most cancers cells [25].

- Immunotherapy pills can help the immune device fight cancer. These pills work by using blockading proteins that prevent the immune system from attacking most cancers cells. For example, pembrolizumab (Keytruda) is an immunotherapy drug that blocks the PD-1 protein, that is regularly used by cancer cells to avoid the immune system [26].
- The immune system can assist save you most cancers from developing within the first location. Immune cells can come across and damage cells that have come to be odd or damaged, that could prevent them from turning into cancerous [27]. Additionally, persistent inflammation can boom the threat of most cancers, and the immune machine plays a key function in regulating infection [28]. The immune system can assist manage most cancers boom and prevent metastasis. Cancer cells can unfold to other elements of the frame through the bloodstream or lymphatic system. However, the immune device can help save you this by using attacking and destroying most cancers cells that have spread [29].
- The immune system can be harnessed to improve most cancers treatment. For example, some chemotherapy tablets can suppress the immune system, that may make it harder for the frame to combat cancer. However, low doses of chemotherapy can selectively suppress regulatory T cells, that can counteract immunosuppression in cancer [30].

IMMUNE CHECKPOINT INHIBITORS

Immune checkpoints are molecules that are gift at the floor of immune cells and help adjust the immune response. They play an essential role in maintaining the balance among immune activation and immune tolerance. When immune checkpoints are activated, they can inhibit the immune response, that could help prevent autoimmune sicknesses and restriction tissue harm. However, cancer cells can hijack those checkpoints to stay away from the immune device and avoid destruction [31].

Key Points, Approximately Immune Checkpoints, and Their Function in Immune Regulation

- Immune checkpoints are molecules which are present at the floor of immune cells, which include T cells and dendritic cells. Immune checkpoints can both set off or inhibit the immune reaction, relying on the context.
- When immune checkpoints are activated, they can inhibit the immune reaction, that may assist save you autoimmune illnesses and restriction tissue harm [32]. Cancer cells can hijack immune checkpoints to evade the immune system and avoid destruction. For instance, some cancer cells explicit excessive levels of the PD-L1 protein, that could bind to the PD-1 receptor on T cells and inhibit their activity [33].
- Immunotherapy tablets can block immune checkpoints and help the immune system understand and assault cancer cells. For instance, pembrolizumab (Keytruda) is an immunotherapy drug that blocks the PD-1 receptor and has been accredited for the remedy of numerous varieties of cancer [34].
- Immune checkpoints also are vital for maintaining immune tolerance and preventing autoimmune diseases. For instance, CTLA-4 is an immune checkpoint that helps prevent T cells from attacking healthy tissues. Dysregulation of immune checkpoints can make a contribution to the development of autoimmune diseases and most cancers. For example, mutations within the CTLA-4 gene have been associated with autoimmune illnesses including type 1 diabetes and rheumatoid arthritis [35].
- Immune checkpoints are molecules that play a critical role in immune regulation with the aid of either activating or inhibiting the immune reaction. They are important for retaining immune tolerance and stopping autoimmune sicknesses, but also can be hijacked with the aid of cancer cells to steer clear of the immune device. Immunotherapy capsules that block immune checkpoints have shown promise in treating most cancers [36].

The Development and Clinical Success of Checkpoint Inhibitors (PD-1, CTLA-4)

Checkpoint inhibitors, which include PD-1 and CTLA-4, were evolved as a novel class of immunotherapeutic sellers for most cancers' treatment. Here are a few key points, about the development and clinical fulfillment of checkpoint inhibitors:

- Checkpoint inhibitors target immune checkpoints, that are molecules that adjust the immune response. PD-1 and CTLA-4 are vital immune checkpoints which can be centered by means of checkpoint inhibitors [37].
- The development of checkpoint inhibitors has been a main breakthrough in cancer remedy. Prior to the improvement of checkpoint inhibitors, most cancers' treatment particularly depended on surgical procedure, chemotherapy, and radiation therapy, that could have vast aspect effects and limited efficacy [38].
- Checkpoint inhibitors have demonstrated remarkable clinical success in treating various types of cancer, including melanoma, lung cancer, and renal cell carcinoma. For example, the combination of ipilimumab and nivolumab, targeting CTLA-4 and PD-1, respectively, has been approved as a standard treatment for intermediate- or poor-risk metastatic renal cell carcinoma patients [39].
- Checkpoint inhibitors have additionally shown long lasting medical hobby, with some sufferers experiencing long-term remission [40].
- Checkpoint inhibitors also can cause immune-related destructive events, which can vary from mild to intense and affect various organs [41].
- Cautious monitoring and management of these adverse events is necessary. Combination treatment options and trade therapeutic modalities, such as small molecule checkpoint inhibitors, are being actively pursued to in addition improve cancer immunotherapy [42].

Combination Therapies Involving Checkpoint Inhibitors

- Combination healing procedures involving checkpoint inhibitors have grown to be a vital place of research in cancer remedy. Combination therapies related to checkpoint inhibitors have shown promise in enhancing the effectiveness of most cancers' immunotherapy [43–45]. For instance, combining immune checkpoint inhibitors with chemotherapy has been shown to be greater effective than chemotherapy alone in treating lung cancer [46].
- The mechanisms that account for the prevalence of authorized checkpoint inhibitor combos relative to their constituent monotherapies stay unknown [47].
- Combination treatment plans concerning checkpoint inhibitors also can help triumph over resistance to single-agent checkpoint blockade [48].
- The tumor microenvironment (TME) plays a critical position in the effectiveness of checkpoint inhibitor combos. Recent studies have centered on figuring out cell and molecular factors in the TME to develop novel aggregate techniques for most cancers' immunotherapy [43].
- Predictive biomarkers can help become aware of patients who are most possibly to advantage from checkpoint inhibitor mixtures [46].
- Despite the promising outcomes of checkpoint inhibitor combos, careful monitoring and management of immune-related negative activities and cautious tracking and control of adverse events is necessary [43].

Combination cures involving checkpoint inhibitors have proven promise in improving the effectiveness of most cancers' immunotherapy. The mechanisms that account for their superiority relative to monotherapies continue to be unknown, however, latest studies has focused on identifying elements within the TME to increase novel combo techniques. Predictive biomarkers can help identify patients who are maximum likely to advantage from checkpoint inhibitor combos, and careful monitoring of unfavorable activities is important.

CAR-T CELL THERAPY

Chimeric Antigen Receptor (CAR) T-cell Therapy

Chimeric Antigen Receptor (CAR) T-cell remedy is a sort of personalized therapy wherein the body's very own T cells are genetically changed to specific CARs, which can be especially targeted to attack cancerous cells.

- CAR T-cellular therapy is a kind of adoptive cellular remedy, where T cells are removed from a patient's blood and genetically changed to express CARs that concentrate on most cancers' cells [49].
- CARs are recombinant receptors for antigens that redirect the specificity and characteristic of T lymphocytes and/or other immune cells in a single molecule [50].
- CAR T-cell remedy has shown incredible efficacy in treating hematological malignancies, along with leukemia and lymphoma [51].
- CAR T-cell therapy is a noticeably personalized treatment, as the T cells are taken from the patient's personal body and modified to target their particular most cancers cells [49].
- CAR T-cell remedy has a few boundaries, which includes on-goal off-tumor toxicity, inefficient accumulation and survival of CAR T cells within the immunosuppressive tumor microenvironment, and challenges targeting solid tumors [52].
- CAR T-cellular remedy has shown promise in treating stable tumors, but extra studies is wanted to conquer the demanding situations associated with this technique [53].
- CAR T-cell therapy can cause intense facet outcomes, inclusive of cytokine launch syndrome and neurotoxicity, which require careful tracking and control [54].

CAR T-cell remedy is a type of personalized therapy wherein T cells are genetically modified to specific CARs that target cancer cells. It has proven notable efficacy in treating hematological malignancies, however has a few boundaries and may cause serious side effects. More studies are needed to conquer the challenges related to CAR T-cellular therapy and to enhance its effectiveness in treating solid tumors.

Engineering and Manufacturing of CAR-T Cells

Engineering and production of CAR-T cells contain several steps, consisting of T cellular isolation, genetic amendment, Expansion and quality control.

- T cells are isolated from a patient's blood using a technique referred to as leukapheresis [55].
- The T cells are then genetically changed to explicit CARs that concentrate on cancer cells. This may be accomplished using viral vectors, along with retroviruses or lentiviruses, or non-viral strategies, together with electroporation or CRISPR-Cas9 gene enhancing [56].
- The modified T cells are then improved inside the laboratory to generate a massive wide variety of CAR-T cells.
- Quality manage measures are taken to make certain that the CAR-T cells are secure and effective. This includes checking out for purity, potency, and sterility [55].
- Manufacturing of CAR-T cells can be complex and steeply-priced, representing a logistical bottleneck for CAR-T cellular manufacturing [57].
- Emerging gene-modifying technologies, which include CRISPR-Cas9, are fostering a brand new paradigm in synthetic biology for the engineering and manufacturing of CAR-T cells [58].
- *In vivo* engineering of CAR-T cells is a promising method for customized cancer immunotherapy, as it can overcome the constraints of *ex vivo* production tactics [59].

Challenges and Potential Future Developments in CAR-T Therapy

CAR-T cellular therapy is a promising technique for most cancers' immunotherapy that includes genetically engineering an affected person's T-cells to specific chimeric antigen receptors (CARs) that could target tumor-related antigens. While CAR-T cell remedy has proven first rate efficacy in some

hematologic malignancies, its medical utility in solid tumors has been restricted via numerous demanding situations. Some of the challenges and potential future trends in CAR-T remedy [60]:

- Challenges
  - *Tumor antigen heterogeneity:* Solid tumors frequently have a complicated and heterogeneous antigen profile, that can make it hard to perceive a single antigen that is expressed on all tumor cells and can be centered by CAR-T cells.
  - *Hostile tumor microenvironment:* Solid tumors can create a hostile microenvironment that may inhibit the characteristic of CAR-T cells and restrict their capability to infiltrate and assault tumor cells [61, 62].
  - *Poor trafficking of CAR-T cells:* CAR-T cells might not be capable of effectively trafficking to and penetrate solid tumors, which can restrict their efficacy [62].
  - *Toxicities:* CAR-T cellular therapy can reason excessive toxicities, such as cytokine release syndrome (CRS) and neurotoxicity, which can be existence-threatening in some cases [63].
- Potential destiny developments
  - *Next-generation CAR-T cells:* Researchers are growing subsequent-technology CAR-T cells which could conquer a number of the demanding situations related to modern-day CAR-T cellular remedy. For instance, a few new CAR-T cells are designed to target multiple antigens or to be activated through a couple of signals, which could increase their efficacy and decrease the chance of antigen escape.
  - *Combination treatment options:* Combination therapies that integrate CAR-T cellular therapy with different treatments, such as checkpoint inhibitors or radiation remedy, can be able to enhance the efficacy of CAR-T cells and triumph over a number of the challenges related to strong tumors [64].
  - *Gene modifying:* Gene editing technology, such as CRISPR/Cas9, can be able to enhance the function of CAR-T cells and make them more effective at targeting on solid tumors.
  - *Allogeneic CAR-T cells:* Allogeneic CAR-T cells, which are derived from a donor in place of the affected person, can be capable to overcome some of the demanding situations related to autologous CAR-T cells, together with the time and value required to fabricate them. However, allogeneic CAR-T cells also deliver the danger of graft-versus-host disorder (GVHD), which can be existence-threatening [65].

Overall, while CAR-T cellular Therapy has shown splendid efficacy in some hematologic malignancies, its medical application in strong tumors has been constrained with the aid of numerous challenges. However, researchers are actively running to increase new and stepped forward CAR-T mobile treatment options that may overcome these demanding situations and enhance the effects for sufferers with strong tumors (Tables 5).

Table 5. CAR-T cell therapy.

Aspect	Description
Chimeric antigen receptor (CAR) T-cell therapy	Personalized therapy using genetically modified T cells to target cancer cells
Engineering and manufacturing	Involves T cell isolation, genetic modification, expansion, and quality control
Challenges and potential developments	Challenges include tumor antigen heterogeneity, hostile tumor microenvironment, and toxicities. Potential developments include next-generation CAR-T cells, combination therapies, gene editing, and allogeneic CAR-T cells

ONCOLYTIC VIRUSES

Oncolytic viruses are a promising method for cancer treatment that involves the use of viruses to selectively goal and kill most cancers cells while sparing normal ones (Table 6 and Figure 1).

- Oncolytic viruses can be engineered to especially target and kill most cancers cells, whilst simultaneously triggering an immune response at the sight of infection [66].

- There are many one-of-a-kind forms of oncolytic viruses which have been advanced and tested in both laboratory settings and in cancer affected person clinical trials.
- Oncolytic viruses have emerged as one of the key cancer immunotherapy agents because of their multi-mechanistic anti-tumor outcomes [67].
- There are several challenges associated with developing a successful oncolytic virus, along with tumor antigen heterogeneity, the adverse tumor microenvironment, terrible trafficking of the virus, and toxicities [68].
- Researchers are developing innovative techniques to optimize the ability of oncolytic viruses, which include engineering the viruses to encode bispecific T cell engagers or combining them with different remedies like immune checkpoint inhibitors or chemotherapy [69, 70].
- Oncolytic viruses have proven promising outcomes in scientific trials for various forms of most cancers, consisting of glioblastoma, but similarly optimization of immunotherapies is needed [71].

Table 6. Oncolytic viruses in cancer treatment.

Aspect	Description
Oncolytic viruses	Viruses engineered to selectively target and kill cancer cells, potentially triggering an immune response
Challenges and potential developments	Challenges include tumor antigen heterogeneity, the adverse tumor microenvironment, poor virus trafficking, and toxicities. Potential developments include next-generation oncolytic viruses and combination therapies.



Figure 1. The process of immunogenic demise of cancer cells induced by the oncolytic virus.

Oncolytic Viruses (T-VEC, HSV-1-based Therapies) and Their Clinical Applications

Oncolytic viruses are viruses which could selectively infect and kill most cancers cells even as sparing normal cells. Two examples of oncolytic viruses are T-VEC and HSV-1-primarily based treatment plans. Here is some information about these viruses and their scientific applications:

- *T-VEC*
  - T-VEC is a genetically changed herpes simplex virus type 1 (HSV-1) that has been engineered to selectively reflect in and kill most cancers cells.
  - It has been permitted by way of the FDA for the remedy of superior cancer, a form of skin cancers.
  - In clinical trials, T-VEC has been proven to enhance usual survival and response rates in patients with advanced melanoma [72].

- *HSV-1-primarily Based Cures*
  - HSV-1 is a commonplace virus that may cause cold sores and genital herpes.
  - It has been engineered to selectively reflect in and kill most cancers cells even as sparing normal cells.
  - HSV-1-based therapies are being studied for the treatment of various types of most cancers, such as glioblastoma (a type of mind cancers), pancreatic cancers, and breast cancers.
  - In clinical trials, HSV-1-primarily based healing procedures have shown promising outcomes in terms of protection and efficacy [73].

Ongoing Research in Oncolytic Virotherapy and its Potential

Oncolytic virotherapy is a promising shape of gene therapy for most cancers that uses viruses as vectors. Recent studies have shown that oncolytic viruses demonstrate a potential for effective treatment in numerous cancer patients [74, 75].

Some ongoing research studies in oncolytic virotherapy and their potential:

- *Oncolytic vaccinia virus (OVV):* OVV has received reputation attributable to its safety, potential for systemic transport, and large gene insertion potential. Recent researches have mounted that viruses altered through genetic modifications can serve as powerful oncolytic vectors to combat adverse tumor environments. Ongoing medical trials are exploring the use of engineered mutated viruses and gene-armed OVVs to reverse the tumor microenvironment and enhance antitumor activity *in vitro* and *in vivo* [76].
- *Oncolytic poliovirus (PVS-RIPO):* PVS-RIPO is a genetically engineered polio virus this is infused at once into the affected person's tumor. Once in the tumor, PVS-RIPO infects and kills tumor cells. PVS-RIPO consists of a genetically changed non-pathogenic model of the oral poliovirus Sabin kind 1. Although this tumor cell killing by alone can also have tumor-fighting outcomes, the probable key to therapy with PVS-RIPO is its ability to harness the patients' immune response against the cancer. Currently, Phase I clinical trials of PVS-RIPO in opposition to glioblastoma are ongoing, and this remedy is showing promising results by using extending the life expectancy of sufferers with recurrent glioblastoma multiforme [74, 75].
- *Triple negative breast cancers:* Oncolytic viruses are being studied as an potential treatment for triple negative breast cancer. A recent observation explored using oncolytic viruses to goal triple negative breast cancer cells and determined that the viruses had been capable of selectively infecting and killing these cells [77].
- *Combination treatments:* Researchers are exploring using oncolytic viruses in combination with other cancers treatments, along with immune checkpoint inhibitors. One have a look at determined that inhibiting an alternative immune checkpoint, CD200, inhibits tumor-brought about immunosuppression without poisonous facet consequences. CD200 protein suppresses immune activation after engaging the CD200 inhibitory receptor, that is restricted to immune cells. By exploring peptide fragments due to protease cleavage of the CD200 protein, researchers discovered that CD200 absolutely features via paired receptors and that positive peptide ligands (CD200 inhibitor) clearly surmount the immunosuppressive results of CD200 to stimulate immune response. This was confirmed in murine glioma models. Researchers lately evolved humanized CD200 inhibitors, which changed into verified *in vitro* measuring the immune reaction of human cells to CMV antigen (pp65 495–503). They conducted a clinical trial in companion dogs with primary gliomas and demonstrated that a dog-specific CD200 inhibitor. In this ongoing clinical trial, the usage of dogs recognized with excessive-grade glioma, receiving a dog particular CD200 inhibitor in combination with the autologous tumor lysate vaccine had superior survival as much as 615 days, relative to 214 days with lysate alone, with no observed toxicity or signs and symptoms of reoccurrence. As a result of these findings, researchers agree with that it is critical to transport ahead with phase I human clinical trials utilizing inhibitor [78].

CHALLENGES AND FUTURE DIRECTIONS

Resistance to Oncolytic Viruses

Oncolytic virotherapy is a promising method in cancer treatment, but there are limitations to its efficacy. Resistance mechanisms encompass transport challenges, upregulation of checkpoints, localization of virus receptors in tight junctions, interferon responses, and aberrant expression of genes involved inside the virus's infection and replication [79].

Resistance to Targeted Cures

Targeted therapies, along with monoclonal antibodies and tyrosine kinase inhibitors, are most of the fundamental remedy alternatives for most cancers. However, important challenges still exist with the presently marketed inhibitors, including boundaries associated with drug types, acquired mechanisms of drug resistance that reason affected person relapse, and tumor heterogeneity [80].

Limitations of Metallodrugs

Metal complexes are substantially used for cancer therapy, but they commonly suffer from low pharmacokinetics, low levels of target site accumulation, steel-mediated off-target reactivity, and development of drug resistance, that could all restrict their efficacy and medical translation. Nanomedicine has arisen as an effective tool to assist conquer these shortcomings [81].

Unknowns about Immune Checkpoint Inhibitors as Antifungal Immunotherapy

There is emerging proof for contributions of checkpoint pathways to the immunopathology of fungal infections, and immune checkpoint inhibitors (ICIs) had been proposed as an antifungal immunotherapy. However, there are numerous unknowns approximately ICIs as an antifungal immune enhancement strategy, such as capacity toxicities, ICI resistance, and the function of mixture therapy [82].

Developments and Emerging Therapies (Neoantigen Vaccines, Personalized Medicine) in Cancer

Neoantigen Vaccines

These vaccines are designed to target tumor-specific antigens (TSAs) also called neoantigens, which arise from somatic mutations in cancer cells neoantigens are presented by MHC molecules and recognized by T lymphocytes, making them ideal immune targets to boom healing specificity and reduce the risk of nonspecific autoimmunity. Personalized neoantigen-primarily based immunotherapies are emerging, and current clinical trials have shown promise [83].

Personalized Medicine

The advancement of precision cancer medicine through thorough interrogation of cancer genomes at the point of care has more advantageous patient stratification and remedy choice techniques in severe most cancers sorts. The intersection of clinical cancers genomics and immuno-oncology has created an opportunity to learn how the tumor and germline genomes effect immune checkpoint blockade reaction, and how the immune machine may be leveraged with know-how of the most cancers genome to more efficaciously stratify patients and tailor immune-unique therapies. Emerging records on genomic resistance to immunotherapies may also inform combination remedy strategies [84].

Nanomedicines

Nanotechnology has proven sizeable potential in organic medication fields, along with drug shipping, diagnostics, and tissue regeneration. Nanomedicines have commonly been developed for cancer analysis and therapy, owing to the enhanced permeability and retention (EPR) effect of strong tumors discovered over 30 years ago. Clinical effects have proven that nanomedicines lessen the systemic toxicity and unfavorable effects of therapeutic agents by altering their pharmacokinetics and biodistributions. Beyond cancer, different packages are emerging in nanomedicines for metabolic, cardiovascular, and infectious illnesses [85].

IMMUNOTHERAPY AND PATIENT OUTCOMES

Impact of Immunotherapy on Patient Survival, Quality of Life, and Long-term Outcomes

Immunotherapy has been proven to enhance affected person survival by way of approximately 5.5 months, irrespective of the standard [86]. Additionally, immunotherapy has been shown to offer patients favorable effects in terms quality of life [87]. Long-term results in patients with advanced and/or metastatic non-small cellular lung, most cancers which completed 2 years of immune checkpoint inhibitors showed that a significantly high share of patients who persisted to experience lengthy-term progression-loose survival [88]. The innovation of immunotherapy goals to treat cancer, improve the quality of life of cancer sufferers, and growth survival charges [89]. A study on cancer patients which dealt with immune checkpoint inhibitors determined that more than 40% of the patients developed a protracted-time period immune-associated side effect [90].

CONCLUSION

In the ever-changing landscape of cancer treatment, the immune system stands as a beacon of hope and change. It has had a remarkable journey from the beginning of late 19th century history to the present, emerging as a precise and targeted method of fighting cancer. Drugs that prevent cancer, eating natural cells dead regeneration, strategic manipulation of the tumor microenvironment, and growth promotion highlight the advances in immunotherapy in this new field. Approaches include monoclonal antibodies, cytokine-based therapies, cell-based interventions, and groundbreaking CAR-T-cell therapies, each highlighting their enormous potential in clinical settings. The role of the immune system in the recognition and control of cancer cells underscores the greater implications of immune therapy in modern cancer care. With research on combination therapy and oncolytic virus development, the future of cancer therapy is bright with promise. The immune system has not only extended patients' lives and improved their quality of life, but it has also become a cornerstone of current and future cancer care, providing new hope and healing for countless individuals.

REFERENCES

1. Aydin Ahmet Murat, *et al*. Prognostic significance of pre-and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy. World J Urol. 2020; 38(10): 2537–2545.
2. Hosseini Reza, *et al*. Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy. Mol Cancer. 2022; 21(1): 15(18p).
3. Zhao Lin, *et al*. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer. Cell Death Dis. 2022; 13(4): 378.
4. Paffenholz Stella V, *et al*. Senescence induction dictates response to chemo-and immunotherapy in preclinical models of ovarian cancer. Proc Natl Acad Sci. 2022; 119(5): e2117754119.
5. Zhang Yuanyuan, Zemin Zhang. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17(8): 807–821.
6. Allison JP. A brief history of immunotherapy. Target Oncol. 2014; 3(1).
7. National Institutes of Health (NIH). Cancer Immunotherapy. (2020). [Online] Available from: https://www.nih.gov/about-nih/what-we-do/nih-turning-discovery-into-health/promise-precision-medicine/cancer-immunotherapy#:~:text=Decades%20of%20NIH%20research%20has,immune%20system%20to%20attack%20tumors.
8. Finegold I. A brief history of allergen immunotherapy. Allergy & Asthma Proceedings. July 2022; 43(4): 248–253.
9. Khan Meshaal, Maker Ajay V, Shikha Jain. The evolution of cancer immunotherapy. Vaccines. 2021; 9(6): 614.
10. ACS. (2014). History of Cancer Treatments: Immunotherapy. [Online]. American Cancer Society. www.cancer.org/cancer/understanding-cancer/history-of-cancer/cancer-treatment-immunotherapy.html.
11. Darvishi Mohammad, *et al*. Recent progress in cancer immunotherapy: Overview of current status and challenges. Pathol Res Pract. 2023; 241: 154241.

12. Fa'ak Faisal, Adi Diab. Cancer Immunotherapy: Overview of Immune Checkpoint Inhibitors. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy: A Handbook for Diagnosis and Management. Cham: Springer; 2021; 31–47.
13. Caruso Dean. Current and future directions for cancer immunotherapy Overview 102. Cancer Forum, 2002; 26(2), 102–104.
14. Beckhove Philipp. Cancer immunotherapy: overview in brief. In: The Tumor Immunoenvironment. Dordrecht: Springer; 2013; 549–565.
15. Tan Wei Chang Colin, *et al*. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun. 2020; 40(4): 135–153.
16. Timmer Florentine EF, *et al*. Pancreatic cancer and immunotherapy: a clinical overview. Cancers. 2021; 13(16): 4138.
17. Mezni Essia, Khalil Behi, Anthony Gonçalves. Immunotherapy and breast cancer: An overview. Curr Opin Oncol. 2022; 34(5): 587–594.
18. Li Xinxin, *et al*. Targeting the RNA m6A modification for cancer immunotherapy. Mol Cancer. 2022; 21(1): 76.
19. Creemers Jeroen HA, *et al*. A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. J Immunother Cancer. 2021; 9(5): e002032.
20. Sethna Zachary, *et al*. 824 High quality neoantigens are immunoedited in long-term pancreatic cancer survivors. *J Immunother Cancer.* 2021; 9(Suppl 2): A1–A1054.
21. Bullock Timothy NJ. Fundamentals of cancer immunology and their application to cancer vaccines. Clin Transl Sci. 2021; 14(1): 120–131.
22. Vu Tamara MSH, *et al*. Theranostics: a fifth pillar of contemporary cancer care? ANZ J Surg. 2022; 92(11): 2782.
23. Deng Yixin, *et al*. Introduction and Application of Death Protein 1. 2022 International Conference on Biotechnology, Life Science and Medical Engineering (BLSME 2022). 2022; 367–376.
24. Huang Haoran, *et al.* T cell proliferation-related genes: Predicting prognosis, identifying the cold and hot tumors, and guiding treatment in clear cell renal cell carcinoma. Front Genet. 2022; 13: 948734.
25. Sharifi Maryam, Jamshidi Arta A, Nazanin Namazi Sarvestani. An adaptive robust control strategy in a cancer tumor-immune system under uncertainties. IEEE/ACM Transactions on Computational Biology and Bioinformatics (TCBB). 2018; 16(3): 865–873.
26. Ertan Kubra, *et al*. The importance of systemic inflammatory response index, systemic immune-inflammation index, and hemoglobin-albumin-lymphocytes-platelets (HALP) score in children with cancer. Iranian J Pediatr. 2021; 31(6): e118121.
27. Huang H, Wu K, Chen L, Lin X. Study on the application of systemic inflammation response index and platelet-lymphocyte ratio in ovarian malignant tumors. International Journal of General Medicine. Dec 2021; 14: 10015–10022.
28. Dang Yangjie, *et al*. The effect of anesthesia on the immune system in colorectal cancer patients. Can J Gastroenterol Hepatol. 2018; 2018: 7940603.
29. Kaur KK, Allahbadia G, Singh M. Importance of controlling obesity and associated immune response changes in prevention and treatment of cancer–with plant therapies of help. Adv Obes Weight Manag Control. 2019; 9(4): 114–116.
30. Ahlmann Martina, Georg Hempel. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol. 2016; 78: 661–671.
31. Nair Varun Sasidharan, *et al*. Epigenetic regulation of immune checkpoints and T cell exhaustion markers in tumor-infiltrating T cells of colorectal cancer patients. Epigenomics. 2020; 12(21): 1871–1882.
32. Wang Ping-Huai, *et al*. The dynamic change of immune checkpoints and CD14+ monocytes in latent tuberculosis infection. Biomedicines. 2021; 9(10): 1479.
33. Funes Samanta C, *et al*. Immune checkpoints and the regulation of tolerogenicity in dendritic cells: implications for autoimmunity and immunotherapy. Autoimmun Rev. 2019; 18(4): 359–368.

34. Hu Min, *et al*. The regulation of immune checkpoints by the hypoxic tumor microenvironment. Peer J. 2021; 9: e11306.
35. Ruedas-Torres Inés, *et al*. Up-regulation of immune checkpoints in the thymus of PRRSV-1-infected piglets in a virulence-dependent fashion. Front Immunol. 2021; 12: 671743.
36. Shang Bing-Bing, *et al*. Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma. Peer J. 2021; 9: e12315.
37. Sasikumar Pottayil G, Murali Ramachandra. Small molecule agents targeting PD-1 checkpoint pathway for cancer immunotherapy: mechanisms of action and other considerations for their advanced development. Front Immunol. 2022; 13: 752065.
38. Godwin James L, *et al*. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discov Med. 2014; 18(101): 341–350.
39. Zhou Xiaohan, *et al.* Synergies of antiangiogenic therapy and immune checkpoint blockade in renal cell carcinoma: from theoretical background to clinical reality. Front Oncol. 2020; 10: 1321.
40. Tenorio-Pedraza Juan Miguel, *et al*. Meta-analysis of preclinical measures of efficacy in immune checkpoint blockade therapies and comparison to clinical efficacy estimates. Transl Med Commun. 2023; 8(1): 17.
41. Tang Xuzhen, *et al*. HuPBL humanized models as a tool to evaluate the efficacy and immune regulation of immune checkpoint inhibitors. Cancer Res. 2017; 77(13_Suppl): 3849–3849.
42. Guo Linlin, *et al*. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). Oncoimmunology. 2022; 11(1): 2127691.
43. Chyuan I-Tsu, Ching-Liang Chu, Ping-Ning Hsu. Targeting the tumor microenvironment for improving therapeutic effectiveness in cancer immunotherapy: focusing on immune checkpoint inhibitors and combination therapies. Cancers. 2021; 13(6): 1188.
44. Puri Sonam, Michael Shafique. Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. Drugs Context. 2020; 9: 2019-9-2.
45. Cheu Jacinth Wing-Sum, Carmen Chak-Lui Wong. Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors. Hepatology. 2021; 74(4): 2264–2276.
46. Maung Tun Zan, *et al*. Immune checkpoint inhibitors in lung cancer: role of biomarkers and combination therapies. Cureus. 2020; 12(5): e8095.
47. Palmer Adam C, *et al*. Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors. Clin Cancer Res. 2022; 28(2): 368–377.
48. Gong Jun, *et al*. Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. Clin Transl Med. 2018; 7(1): 32(16p).
49. Pagel John M, Howard Jack West. Chimeric antigen receptor (CAR) T-cell therapy. JAMA Oncol. 2017; 3(11): 1595–1595.
50. Zhang C, Kasi A. Chimeric Antigen Receptor (CAR) T-Cell Therapy. Treasure Island, FL: StatPearls; 2019.
51. Hofmann Susanne, *et al*. Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML). J Clin Med. 2019; 8(2): 200.
52. Sakoda Yukimi, Koji Tamada. Chimeric antigen receptor (CAR)-T cell therapy. Nihon rinsho (Japanese Journal of Clinical Medicine). 2017; 75(2): 281–287.
53. Schubert M-L, *et al*. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021; 32(1): 34–48.
54. Fraietta Joseph A, *et al.* Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018; 24(5): 563–571.
55. Dimitri Alexander, Friederike Herbst, Fraietta Joseph A. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022; 21(1): 78.

56. Wagner Dimitrios L, *et al*. Sustainable clinical development of CAR-T cells–switching from viral transduction towards CRISPR-Cas gene editing. Front Immunol. 2022; 13: 865424.
57. Agarwalla Pritha, *et al*. Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells. Nat Biotechnol. 2022; 40(8): 1250–1258.
58. Larson Rebecca C, Maus Marcela V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021; 21(3): 145–161.
59. Huckaby Justin T, *et al*. Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells. J Immunother Cancer. 2021; 9(9): e002737.
60. El-Daly Sherien M, Jihan Hussein. Genetically engineered CAR T-immune cells for cancer therapy: recent clinical developments, challenges, and future directions. J Appl Biomed. 2019; 17(1): 11.
61. Poorebrahim Mansour, *et al*. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects. Crit Rev Clin Lab Sci. 2019; 56(6): 393–419.
62. Srour Samer A, Serkan Akin. Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future. Journal of Immunotherapy and Precision Oncology (JIPO). 2023; 6(1): 19–30.
63. Gor Dhairya, *et al*. The Diagnostic and Treatment Challenges of Concomitant Mantle Cell Lymphoma and IgM Myeloma. Eur J Case Rep Intern Med. 2022; 9(7): 003463.
64. Golubovskaya Vita, *et al*. Major highlights of the CAR-TCR Summit, Boston, 2016. Anti-Cancer Agents Med Chem (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 2017; 17(10): 1344–1350.
65. Beck Caroline, *et al.* Tissue-specific targeting for cardiovascular gene transfer. Potential vectors and future challenges. Curr Gene Ther. 2004; 4(4): 457–467.
66. Lauer Ulrich M, Julia Beil. Oncolytic viruses: challenges and considerations in an evolving clinical landscape. Future Oncol. 2022; 18(24): 2713–2732.
67. Rahman Masmudur M, Grant McFadden. Oncolytic viruses: newest frontier for cancer immunotherapy. Cancers. 2021; 13(21): 5452.
68. Tian Yaomei, Daoyuan Xie, Li Yang. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther. 2022; 7(1): 117.
69. Heidbuechel Johannes PW, Engeland Christine E. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J Hematol Oncol. 2021; 14(1): 1–24.
70. Malogolovkin Alexander, *et al*. Combinatorial approaches for cancer treatment using oncolytic viruses: projecting the perspectives through clinical trials outcomes. Viruses. 2021; 13(7): 1271.
71. Suryawanshi Yogesh R, Schulze Autumn J. Oncolytic viruses for malignant glioma: On the verge of success? Viruses. 2021; 13(7): 1294.
72. Goins William F, *et al*. Engineering HSV-1 vectors for gene therapy. Herpes Simplex Virus: Methods and Protocols. 2014; 63–79.
73. Goins William F, *et al*. Engineering HSV-1 vectors for gene therapy. Herpes simplex virus: Methods and protocols. 2020; 2060: 73–90.
74. Marinova Zhenya, *et al*. Oncolytic virotherapy-can a poliovirus cure cancer? Scr Sci Pharm. 2016; 3: 12.
75. Ye L, Chan T, Kryskiv O, Skoryk M. Scripta Scientifica Pharmaceutica. 2015; 1: 39–45. Scripta Scientifica Pharmaceutica. [Online] Available at: https://journals.mu-varna.bg/index.php/ssp/index.
76. Li Mengyuan, *et al*. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review. Cancer Biol Med. 2023; 20(9): 646–661.
77. Jin Shengye, *et al*. Oncolytic viruses for triple negative breast cancer and beyond. Biomark Res. 2021; 9(1): 71(6p).
78. Alayo Quazim, *et al*. IMMU-12. The Histone Deacetylase Inhibitor Valproic Acid Augments the Susceptibility of Oncolytic Virus-Infected Glioblastoma Cells to PD-1 Blockade Therapy. Neuro-Oncology. 2017; 19(Suppl 6): vi115.
79. Goradel Nasser Hashemi, *et al*. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses. Future Oncol. 2021; 18(2): 245–259.
80. Miller Megan Jo, Kevin Chu Foy, Kaumaya Pravin TP. Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discov Med. 2013; 15(82): 166–176.

81. Peña Quim, *et al.* Metallodrugs in cancer nanomedicine. Chem Soc Rev. 2022; 51(7): 2544–2582.
82. Wurster Sebastian, Watowich Stephanie S, Kontoyiannis Dimitrios P. Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions. Front Immunol. 2022; 13: 1018202.
83. Pan Ren-You, *et al*. Recent development and clinical application of cancer vaccine: targeting neoantigens. J Immunol Res. 2018; 2018: 4325874.
84. Van Allen Eliezer. Abstract SY18-02: Immunogenomics and precision cancer medicine. Cancer Res. 2016; 76(14_Supp): SY18–02.
85. Zhang Ning. Promoting the bench-to-bedside translation of nanomedicines. Med Rev. 2023; 3(1): 1–3.
86. Amin Saber, *et al*. Impact of immunotherapy on the survival of patients with cancer and brain metastases. J Natl Compr Canc Netw. 2020; 18(7): 832–840.
87. Beaulieu Elizabeth, *et al*. Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams. Qual Life Res. 2022; 31(8): 2357–2366.
88. Kim Hongsik, *et al.* Long-term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11). Cancer. 2022; 128(4): 778–787.
89. Fragkiadakis Georgios F, *et al.* Investigating the Quality of Life for Cancer Patients and Estimating the Cost of Immunotherapy in Selected Cases. Cureus. 2022; 14(12): e32390.
90. Nadia Jaber. (2021 Apr 30). Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors. [Online]. National Cancer Institute. www.cancer.gov/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects.

